Roche receives CE Mark for minimally invasive blood test to help rule out Alzheimer's disease
The minimally invasive, blood-based test can serve as a rule out for Alzheimer's pathology, reducing the need for confirmatory testing with a negative result.
Data from clinical study supports use in primary care for people with varying signs of cognitive decline.
Basel, 23 July 2025 – Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today it has received CE Mark for its Elecsys® pTau181 test to measure phosphorylated Tau (pTau) 181 protein which is an indicator of amyloid pathology, a hallmark of Alzheimer's disease. The test, which has been developed in collaboration with Eli Lilly and Company, can be used by clinicians in conjunction with other clinical information to rule out Alzheimer's disease as the cause of cognitive decline. This could avoid the need for further confirmatory investigation for patients testing negative.
'The burden of Alzheimer's disease on society and healthcare systems is increasing as the world's population ages,' said Matt Sause, CEO of Roche Diagnostics. 'With Elecsys pTau181, doctors can give patients and their caregivers the clarity they need when establishing the cause of cognitive decline. By enabling an earlier and less invasive diagnosis, this test has the potential to improve patient outcomes and decrease costs for healthcare systems worldwide.'
Barriers to early and accurate diagnosis of Alzheimer's disease exist across the world. Up to 75% of people living with symptoms are not diagnosed, and those who have received a diagnosis waited nearly three years on average after symptom onset.1 The identification of amyloid pathology is critical for Alzheimer's diagnosis and treatment. Current methods to confirm amyloid pathology – including positron emission tomography (PET) and cerebrospinal fluid (CSF) assessment – can be expensive, difficult to access and invasive. With a negative Elecsys pTau181 blood test, people can avoid further unnecessary investigations for Alzheimer's using CSF or PET and can identify the care pathway that is right for them.
Clinical study results support that the test can be implemented effectively across care settings, including primary care, where most patients first seek help for cognitive concerns. Those with positive results are then able to undergo further testing, supporting earlier identification of Alzheimer's pathology. This is key to accessing new treatments that are most effective when used early in the disease progression, enabling patients to make informed decisions about their future care.
Clinical data support the Elecsys pTau181 test for varying signs of cognitive decline
The CE Mark for the Elecsys pTau181 blood test was based on data from a prospective, multicentre study, which included 787 patients across the US, Europe and Australia. The study showed the test was able to rule out Alzheimer's disease with a high negative predictive value (NPV) of 93.8% based on a 22.5% prevalence of amyloid positivity according to positron emission tomography (PET) scans, with 83.6% sensitivity. The rule out performance of the test was only minimally impacted by the patients' age, gender, body mass index or impaired kidney function.
This global, prospectively-collected, diagnostic registrational clinical study was the first of its kind in the industry to investigate the test's clinical performance in a diverse patient population, aged 55-80 years old that reflects as closely as possible the patients who could benefit from the test. It involved a subset of patients from a wider study looking at a highly diverse set of patients with broad inclusion criteria, to ensure the test could be used effectively across different geographies and ethnicities.
Elecsys pTau217 blood test
Roche is also developing the Elecsys pTau217 blood test, an in-vitro diagnostic immunoassay for the quantitative determination of the protein Phospho-Tau (217P) in human plasma for use as an aid in identifying amyloid pathology. Recent data presented on Elecsys pTau217 showed that it was able to accurately detect amyloid pathology and was more stable than a pTau217/Aβ42 ratio in blood and plasma samples at room and refrigerator temperatures. Together with the high throughput and full automation of the assay, these data support the potential of Elecsys pTau217 as an accurate standalone test that could be scaled up for broad implementation in routine clinical practice worldwide across Roche's unmatched installed base.
About Roche in Alzheimer's
With more than two decades of scientific research in Alzheimer's disease, Roche is working towards a day when we can detect and treat the disease early, in order to stop or even prevent its progression to preserve what makes people who they are. Today, the company's Alzheimer's disease portfolio spans investigational medicines for different targets, types and stages of the disease, including trontinemab. On the diagnostics side, it also includes approved and investigational tools, including digital, blood-based tests and CSF assays, aiming to more effectively detect, diagnose and monitor the disease. Yet the global challenges of Alzheimer's disease go well beyond the capabilities of science, and making a meaningful impact requires collaboration both within the Alzheimer's community and outside of healthcare. Roche will continue to work together with numerous partners with the hope to transform millions of lives.
About Roche
Founded in 1896 in Basel, Switzerland, as one of the first industrial manufacturers of branded medicines, Roche has grown into the world's largest biotechnology company and the global leader in in-vitro diagnostics. The company pursues scientific excellence to discover and develop medicines and diagnostics for improving and saving the lives of people around the world. We are a pioneer in personalised healthcare and want to further transform how healthcare is delivered to have an even greater impact. To provide the best care for each person we partner with many stakeholders and combine our strengths in Diagnostics and Pharma with data insights from the clinical practice.
For over 125 years, sustainability has been an integral part of Roche's business. As a science-driven company, our greatest contribution to society is developing innovative medicines and diagnostics that help people live healthier lives. Roche is committed to the Science Based Targets initiative and the Sustainable Markets Initiative to achieve net zero by 2045.
Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan.
For more information, please visit www.roche.com .
All trademarks used or mentioned in this release are protected by law.
References
[1] Alzheimer's Disease International. World Alzheimer Report 2022 [Internet; cited April 2025]. Available from: https://www.alzint.org/resource/world-alzheimer-report-2022/ . Last accessed: April 2025
Roche Global Media Relations
Phone: +41 61 688 8888 / e-mail: [email protected] Hans Trees, PhD
Phone: +41 79 407 72 58 Sileia Urech
Phone: +41 79 935 81 48 Nathalie Altermatt
Phone: +41 79 771 05 25 Lorena Corfas
Phone: +41 79 568 24 95 Simon Goldsborough
Phone: +44 797 32 72 915 Karsten Kleine
Phone: +41 79 461 86 83 Kirti Pandey
Phone: +49 172 6367262 Yvette Petillon
Phone: +41 79 961 92 50 Dr Rebekka Schnell
Phone: +41 79 205 27 03
Roche Investor Relations
Investor Relations North America Loren KalmPhone: +1 650 225 3217
e-mail: [email protected]
Attachment Media Investor Release Elecsys pTau181 CE Mark English
Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same.
Ahmedabad Plane Crash
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Indianapolis Star
10 hours ago
- Indianapolis Star
GEN and Sulfateq BV Announce Positive Phase 1 Trial Data on Investigational Drug SUL-238 for Alzheimer's and Other Neurodegenerative Diseases
Phase 1 results demonstrate that SUL-238, a first-in-class, orally administered, mitochondria-directed drug candidate, is safe and well-tolerated in healthy elderly volunteers, showing a favourable pharmacokinetic profile and high brain penetration. These findings support the advancement of SUL-238 into further clinical development for Alzheimer's and other neurodegenerative diseases. ANKARA, TR / ACCESS Newswire / July 28, 2025 / GEN Pharmaceuticals ( Türkiye's leading specialty pharmaceutical company, announced positive results from its Phase 1 clinical trial evaluating the safety, tolerability, and pharmacokinetics (PK) of first-in-class and novel orally administered mitochondria-directed drug candidate SUL-238 in healthy elderly volunteers. The findings were presented at the Alzheimer's Association International Conference 2025 (AAIC ®) in Toronto. This single oral ascending dose (SAD) Phase 1, first-in-human, randomized, double-blind, placebo-controlled study was conducted in three parts, involving a total of 53 healthy elderly adults. Part 1 included 6 cohorts (50, 100, 250, 500, 1000, and 2000 mg orally, n=23). In Part 2, the PK of a single 1000 mg oral dose was investigated in 10 healthy elderly adults. In Part 2B, the food effect was assessed using a randomized, single oral 2000 mg dose, two-treatment, two-period, crossover design (n=20). The trial results showed that single oral doses of 50-2000 mg of SUL-238 were safe and well-tolerated, while demonstrating a favourable PK profile and high cerebrospinal fluid (CSF) penetration. These findings make SUL-238 a promising candidate for further clinical development in neurodegenerative diseases, including Alzheimer's disease. No adverse effects (AEs) limited dose escalation, AE rates were comparable between SUL-238 and placebo, and all AEs were mild or moderate. The mean terminal elimination half-life was 0.86-3.80 hours, and the time to maximum plasma concentration was 0.50-1.39 hours. Under fed conditions, maximum plasma concentration (C max) and area under the plasma concentration-time curve (AUC 0-∞) decreased by 50% and 60%, respectively. CSF-to-plasma percentages at 2 and 8 hours post-dose were 21.1% (±6.6%) and 74.2% (±46.0%). Abidin Gülmüş, Chairman of GEN, stated: 'We are very encouraged by these promising first-in-human results, marking an important step forward in our mission to address the underlying biology of Alzheimer's disease.' Nadir Ulu, MD, PhD, Vice President of R&D at GEN, added: 'With its excellent safety and PK profile in this Phase 1 trial, combined with robust preclinical data, SUL-238 represents a strong candidate for further clinical development to meet the critical unmet needs in neurodegenerative diseases, including Alzheimer's disease.' About SUL-238 SUL-238 is a novel, first-in-class, hibernation-derived small molecule that targets mitochondria, the cell's 'powerhouse.' It supports mitochondrial bioenergetics via complex I/IV activation and has improved mitochondrial function in rodent models of neurodegenerative, cardiovascular, and renal diseases, as well as aging. SUL-238 crosses the blood-brain barrier and has undergone extensive safety evaluation in preclinical and Phase 1 studies. GEN licenses SUL-238 from Sulfateq BV for neurodegenerative disease applications. About GEN: Founded in 1998, GEN is Türkiye's leading specialty pharmaceutical company, focused on developing innovative therapies across multiple therapeutic areas. GEN manufactures high-quality, competitive products at its GMP-certified facility and pursues original drug development through two dedicated R&D centers and investments. About Sulfateq: Sulfateq B.V. is an early-stage Dutch biotech company that fosters strategic collaborations with academic and industrial research centers to accelerate the development of innovative new medicines. It has developed a novel class of small molecules, the SUL-compounds, that maintain mitochondrial health. Contact Information Bulutay Güneş Sr. Head of Corporate Brand Ali Ketencioğlu Investor Relations Manager Kees van der Graaf Sulfateq CEO View the original press release on ACCESS Newswire The post GEN and Sulfateq BV Announce Positive Phase 1 Trial Data on Investigational Drug SUL-238 for Alzheimer's and Other Neurodegenerative Diseases appeared first on DA80 Hub.
Yahoo
13 hours ago
- Yahoo
Early results from major clinical trial show healthy lifestyle slows cognitive decline
Phyllis Jones wakes up every morning to work up a sweat in countries all over the world, 'and even sometimes on the moon,' she said, thanks to her favorite workout gadget, a virtual reality headset. Her focus on exercise is light-years away from where Jones, 66, of Aurora, Illinois, was just a few years ago. She had prediabetes, and her cholesterol and blood pressure levels were inching up. She was totally sedentary after falling into deep depression. 'I was in bed. I didn't care at all. I was just spiraling,' Jones said. She was probably also destined to lose her ability to think clearly. Jones' mother and grandmother died of vascular dementia, a condition that occurs when the body can't pump enough blood to the brain. Other family members had the disease, too. 'Watching two generations suffer made me determined to break the cycle for myself,' Jones said. 'I'm not that person anymore.' Four years ago, Jones joined a major clinical trial, called U.S. POINTER, that aimed to figure out how older adults at high risk for dementia can stay healthier longer. Half of the more than 2,000 participants were given advice on a healthy lifestyle, including diet and exercise. The other half was thrust into a structured, team-based program that gave participants goals to transform their lifestyles. The program included meeting with experts and other participants regularly, as well as brain exercises and aerobics classes. Participants were instructed to follow the MIND diet, which trades processed foods for whole grains, fruits, leafy greens and other vegetables. The researchers evaluated cognitive function by measuring memory, the ability to focus while juggling multiple tasks, and how quickly people interpreted and responded to information. After two years, both groups showed progress. But people in the structured group saw greater benefits. 'Our conservative estimate shows that, relative to the self-guided group, the structured group performed at a level comparable to adults who were one to two years younger in age,' said Laura Baker, lead researcher and a gerontology professor at Wake Forest University School of Medicine and Advocate Health in Winston-Salem, North Carolina. 'This is what's giving folks additional resilience against cognitive decline,' she said. Greater support and accountability in the structured group were key benefits. 'We're going to tell you what to do, but we're also going to help you get there, and we're going to work with you as a partner to meet you where you are,' Baker said during a news briefing about the findings Monday at the Alzheimer's Association International Conference in Toronto. The research, published simultaneously in the Journal of the American Medical Association, is the first large-scale randomized controlled trial to show that organized, sustainable lifestyle interventions can have a measurable impact on brain health. It's an important finding as the nation is on a path to double the number of people living with dementia by 2060. About 10% of Americans over age 65 have been diagnosed with dementia, according to the Centers for Disease Control and Prevention. Nearly 7 million people in the U.S. have Alzheimer's, the most common type of dementia. While some drugs may slow how quickly dementia develops, there is no cure. 'Some people are scared, thinking there's nothing you can do' to ward off dementia, said Dr. Richard Isaacson, a neurologist and researcher at the Institute for Neurodegenerative Diseases in Florida. The new findings, he said, show that 'we're not powerless in the fight against cognitive decline and Alzheimer's disease.' Isaacson, who formerly directed the Alzheimer's Prevention Clinic at NewYork-Presbyterian/Weill Cornell Medical Center, was not involved with the new research. This isn't the only study to link lifestyle to a delay in dementia. Other research presented at the Alzheimer's Association conference Monday found that regular walking can protect the brains of people with a genetic risk for Alzheimer's. The beauty of lifestyle interventions now proven to help keep cognition sharp is that they can be applied universally, said Rachel Wu, an associate professor of psychology who researches cognition in older adults at the University of California, Riverside. 'There's no downside, no side effects to doing this stuff, except just the time it takes,' Wu said. POINTER trial researchers also took blood samples and scanned participants' brains, looking for amyloid and tau, proteins associated with Alzheimer's disease that form plaques and tangles in the brain. Those samples will be included in a future analysis of study participants, said Heather Snyder, a POINTER researcher and senior vice president of medical and scientific relations at the Alzheimer's Association. 'If you have this biology, do you see a better response? Less response?' she said. 'That's the kind of meaningful question we're going to be able to ask with this data.' Additional findings are expected within the year, Snyder said. Jones is eager to see those results when they're available. 'I don't know what they saw in my brain, but I know I'm a different person,' Jones said. She's lost 30 pounds and is no longer considered prediabetic or a candidate for statins to reduce her cholesterol. 'I'm going to keep moving, eating right, socializing, monitoring my comorbidities,' she said. 'I'm going to take care of myself.' This article was originally published on Solve the daily Crossword
NBC News
14 hours ago
- NBC News
Early results from major clinical trial show healthy lifestyle slows cognitive decline
Phyllis Jones wakes up every morning to work up a sweat in countries all over the world, 'and even sometimes on the moon,' she said, thanks to her favorite workout gadget, a virtual reality headset. Her focus on exercise is light-years away from where Jones, 66, of Aurora, Illinois, was just a few years ago. She had prediabetes, and her cholesterol and blood pressure levels were inching up. She was totally sedentary after falling into deep depression. 'I was in bed. I didn't care at all. I was just spiraling,' Jones said. She was probably also destined to lose her ability to think clearly. Jones' mother and grandmother died of vascular dementia, a condition that occurs when the body can't pump enough blood to the brain. Other family members had the disease, too. 'Watching two generations suffer made me determined to break the cycle for myself,' Jones said. 'I'm not that person anymore.' Four years ago, Jones joined a major clinical trial, called U.S. POINTER, that aimed to figure out how older adults at high risk for dementia can stay healthier longer. Half of the more than 2,000 participants were given advice on a healthy lifestyle, including diet and exercise. The other half was thrust into a structured, team-based program that gave participants goals to transform their lifestyles. The program included meeting with experts and other participants regularly, as well as brain exercises and aerobics classes. Participants were instructed to follow the MIND diet, which trades processed foods for whole grains, fruits, leafy greens and other vegetables. The researchers evaluated cognitive function by measuring memory, the ability to focus while juggling multiple tasks, and how quickly people interpreted and responded to information. After two years, both groups showed progress. But people in the structured group saw greater benefits. 'Our conservative estimate shows that, relative to the self-guided group, the structured group performed at a level comparable to adults who were one to two years younger in age,' said Laura Baker, lead researcher and a gerontology professor at Wake Forest University School of Medicine and Advocate Health in Winston-Salem, North Carolina. 'This is what's giving folks additional resilience against cognitive decline,' she said. Greater support and accountability in the structured group were key benefits. 'We're going to tell you what to do, but we're also going to help you get there, and we're going to work with you as a partner to meet you where you are,' Baker said during a news briefing about the findings Monday at the Alzheimer's Association International Conference in Toronto. The research, published simultaneously in the Journal of the American Medical Association, is the first large-scale randomized controlled trial to show that organized, sustainable lifestyle interventions can have a measurable impact on brain health. It's an important finding as the nation is on a path to double the number of people living with dementia by 2060. About 10% of Americans over age 65 have been diagnosed with dementia, according to the Centers for Disease Control and Prevention. Nearly 7 million people in the U.S. have Alzheimer's, the most common type of dementia. While some drugs may slow how quickly dementia develops, there is no cure. 'Some people are scared, thinking there's nothing you can do' to ward off dementia, said Dr. Richard Isaacson, a neurologist and researcher at the Institute for Neurodegenerative Diseases in Florida. We're not powerless in the fight against cognitive decline. Dr. Richard Isaacson The new findings, he said, show that 'we're not powerless in the fight against cognitive decline and Alzheimer's disease.' Isaacson, who formerly directed the Alzheimer's Prevention Clinic at NewYork-Presbyterian/Weill Cornell Medical Center, was not involved with the new research. This isn't the only study to link lifestyle to a delay in dementia. Other research presented at the Alzheimer's Association conference Monday found that regular walking can protect the brains of people with a genetic risk for Alzheimer's. The beauty of lifestyle interventions now proven to help keep cognition sharp is that they can be applied universally, said Rachel Wu, an associate professor of psychology who researches cognition in older adults at the University of California, Riverside. 'There's no downside, no side effects to doing this stuff, except just the time it takes,' Wu said. POINTER trial researchers also took blood samples and scanned participants' brains, looking for amyloid and tau, proteins associated with Alzheimer's disease that form plaques and tangles in the brain. Those samples will be included in a future analysis of study participants, said Heather Snyder, a POINTER researcher and senior vice president of medical and scientific relations at the Alzheimer's Association. 'If you have this biology, do you see a better response? Less response?' she said. 'That's the kind of meaningful question we're going to be able to ask with this data.' Additional findings are expected within the year, Snyder said. Jones is eager to see those results when they're available. 'I don't know what they saw in my brain, but I know I'm a different person,' Jones said. She's lost 30 pounds and is no longer considered prediabetic or a candidate for statins to reduce her cholesterol. 'I'm going to keep moving, eating right, socializing, monitoring my comorbidities,' she said. 'I'm going to take care of myself.'
